Results 141 to 150 of about 132,280 (264)

Erbium-doped nonablative fractional laser therapy for postinflammatory hyperpigmentation and atrophic scarring due to discoid lupus erythematosus in a patient with systemic lupus erythematosus. [PDF]

JAAD Case Rep
Acevedo-Fontanez LA, Anshelevich E, Kim YJ, Shayegan L, Mortelliti C, Vleugels RA, Shahriari N.   +6 more
europepmc   +1 more source

A Rare Case of Lichen Planus/Discoid Lupus Erythematosus Overlap Syndrome and Its Successful Treatment. [PDF]

Clin Case Rep
Meghwar S, Batra M, Shabbir NZ, Devi P, Singh A, Ikram A, Verma A.   +6 more
europepmc   +1 more source

Discoid lupus erythematosus in a welder

Dermatologica Sinica, 2020
Toshiyuki Yamamoto, Yuka Hanami
openaire   +3 more sources

Wolf and the Dagger: A Rare Overlap. [PDF]

Cureus
Tammana M, Patnaik SS, Parida MK, Tripathy SR, Das BK.   +4 more
europepmc   +1 more source

Analytical study on systemic lupus erythematosus and its association with cutaneous manifestations. [PDF]

Bioinformation
Pavani N, Dua H, Shareef MZ, Joy M, Hammigi T, Farook S, Karki K.   +6 more
europepmc   +1 more source

Chronic Inflammation Promotes Skin Carcinogenesis in Cancer-Prone Discoid Lupus Erythematosus.

Journal of Investigative Dermatology, 2019
Anniek Zaalberg, Sara Moradi Tuchayi, A. Ameri, K. Ngo, T. Cunningham, J. Eliane, Maia Livneh, T. Horn, I. Rosman, A. Musiek, M. Anadkat, S. Demehri   +11 more
semanticscholar   +1 more source

A case of vitiligo secondary to discoid lupus erythematosus treated with tofacitinib. [PDF]

Medicine (Baltimore)
Jin S, Wang S, Jin S, Tang C, Wang P.
europepmc   +1 more source

Anifrolumab for refractory discoid lupus: Two case reports of successful outcomes in Saudi Arabia. [PDF]

Medicine (Baltimore)
Aljohani R.
europepmc   +1 more source

Serum Vitamin D Level and Disease Activity in Patients With Systemic Lupus Erythematosus. [PDF]

Cureus
Oo ATZ, Oo WT, Tun KL, Myint AK, Thu Zar Aye M, Khin NE, Sone KP, Sonn P.   +7 more
europepmc   +1 more source

Enpatoran, a first-in-class, selective, orally administered toll-like receptor 7/8 inhibitor, in systemic and cutaneous lupus erythematosus: results from a randomised, placebo-controlled phase Ib study. [PDF]

Lupus Sci Med
Witte T, Fernandez-Ruiz R, Abramova N, Weinelt D, Moreau F, Klopp-Schulze L, Shaw J, Denis D, Wenzel J.   +8 more
europepmc   +1 more source